TY - JOUR
T1 - Immunomodulation in asthma
T2 - A distant dream or a close reality?
AU - Bharadwaj, Arpita
AU - Agrawal, Devendra K.
PY - 2004/4
Y1 - 2004/4
N2 - The search for new treatments of asthma or any other disease for that matter is an infinite exercise. The scope for discovering new forms of treatment has increased now more than ever due to a better understanding of the molecular pathogenesis of the disease. Regulation of biomolecular or immunological events could occur at numerous points in the disease pathogenesis. This review describes the strategies to regulate the inappropriate immune responses that are elicited after exposure to an allergen. One such successful therapy is treatment with omalizumab, the anti-IgE antibody. Other therapies include cytokine antagonists, transcription factor antagonists, immunostimulatory DNA therapy, cytokine therapy and anti-T cell strategies. All these agents have been shown to be promising and could serve as an alternative approach to the treatment of asthma and maybe other allergic diseases.
AB - The search for new treatments of asthma or any other disease for that matter is an infinite exercise. The scope for discovering new forms of treatment has increased now more than ever due to a better understanding of the molecular pathogenesis of the disease. Regulation of biomolecular or immunological events could occur at numerous points in the disease pathogenesis. This review describes the strategies to regulate the inappropriate immune responses that are elicited after exposure to an allergen. One such successful therapy is treatment with omalizumab, the anti-IgE antibody. Other therapies include cytokine antagonists, transcription factor antagonists, immunostimulatory DNA therapy, cytokine therapy and anti-T cell strategies. All these agents have been shown to be promising and could serve as an alternative approach to the treatment of asthma and maybe other allergic diseases.
UR - http://www.scopus.com/inward/record.url?scp=4444241839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4444241839&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2004.02.001
DO - 10.1016/j.intimp.2004.02.001
M3 - Short survey
C2 - 15099527
AN - SCOPUS:4444241839
VL - 4
SP - 495
EP - 511
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
IS - 4
ER -